Sarepta's Worst Week: A Black Box, 500 Pink Slips, and a $20 Stock
Sarepta just added a black box warning to its only approved gene therapy while cutting a third of its workforce. The company that was supposed to prove gene therapy could go mainstream is now fighting for survival at $20 a share.
The Kind of Monday Nobody Wants
Imagine your doctor tells you that you need surgery and that your insurance is being canceled. At the same time. That's roughly the week Sarepta Therapeutics just had.
The gene therapy company slapped a black box warning on Elevidys, its flagship Duchenne muscular dystrophy treatment, while simultaneously announcing it would cut roughly 500 jobs, about 36% of its workforce. In pharma, a black box warning is the FDA's version of a skull and crossbones on the label. It's the most serious safety alert a drug can carry and still remain on the market. Pairing that with a massive layoff doesn't exactly scream confidence.
Sarepta's stock now hovers around $20.81, and analysts can't agree on whether the company is a turnaround story or a cautionary tale. Their price targets range from $5 to $38, which is less "disagreement" and more "nobody has any idea what happens next."
What the Black Box Actually Says
The new boxed warning centers on acute serious liver injury and acute liver failure, including fatal outcomes. Liver enzymes and bilirubin (a marker of liver damage) can spike within eight weeks after a patient receives the one-time infusion. Patients with preexisting liver disease face even higher risk.
This isn't a surprise that came out of nowhere. In 2025, two non-ambulatory Duchenne patients died from acute liver failure after receiving Elevidys, triggering an FDA safety review. The agency responded by restricting the drug's label to ambulatory patients aged 4 and older with a confirmed gene mutation. Non-ambulatory patients, the ones who arguably need treatment most, were essentially locked out.
The liver risk isn't the only concern on the label, either. Elevidys carries warnings for serious infections (because the immunosuppressants given alongside the therapy lower the body's defenses), allergic reactions during infusion, and a rare but serious condition called , which causes severe muscle weakness. There's also a signal for (heart inflammation), with about a 1.6% incidence rate in clinical trials. The FDA now requires weekly heart monitoring for the first month after infusion.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
immune-mediated myositis
myocarditis
Think of it like buying a car that goes really fast but has a growing list of recalls. At some point, people start eyeing other options.
500 People, $400 Million, and a Shrinking Pipeline
The layoffs are designed to save roughly $400 million per year: about $120 million from payroll and another $300 million from shelving lower-priority pipeline programs. Sarepta is essentially performing triage on its own research portfolio.
The company plans to pause most of its gene therapy programs for limb-girdle muscular dystrophy (LGMD), a group of related muscle-wasting diseases that represented a significant chunk of its R&D ambitions. Instead, Sarepta says it will double down on Elevidys and its newer siRNA platform, a different technology that silences disease-causing genes rather than replacing them.
The restructuring should lower annual R&D and administrative spending to $800 million to $900 million, down from what had been a much higher burn rate. That's the silver lining, if you squint: the company is trying to reach profitability rather than spend its way to oblivion.
But cutting 36% of your people while your lead product gets the scariest possible safety label? That's not a company playing offense. That's a company playing survival.
The Revenue Roller Coaster
Elevidys was supposed to be a blockbuster. For a brief, shining moment, it looked like one. In Q1 2025, the drug posted $375 million in net product revenue for a single quarter. That's a monster number for a rare disease therapy.
Then the safety issues hit, the label got restricted, and the revenue cliff arrived.
By Q2 2026, quarterly Elevidys revenue had fallen to $98.1 million, a 74% drop from that Q1 2025 peak. Full-year 2025 revenue came in at $898.7 million, still impressive on paper but trending sharply in the wrong direction. Management guided 2026 total product revenue at $1.2 billion to $1.3 billion, with Elevidys expected to be flat or down compared to recent quarters.
H.C. Wainwright, one of the more bearish voices on Wall Street, maintains a Sell rating with a $5 price target. Their argument: revenue is falling about 20% year over year, and the safety overhang isn't going away. On the other side, J.P. Morgan recently nudged its target up to $23 from $19, keeping a Hold. The consensus rating across about 20 analysts is essentially "Hold" with an average target in the low-to-mid $20s.
Translation: most of Wall Street thinks the stock is roughly fairly priced and nobody wants to pound the table.
A Disease That Desperately Needs Better Options
Duchenne muscular dystrophy is devastating. It primarily affects boys, progressively destroying muscle tissue until patients lose the ability to walk, then breathe. The current standard of care still relies heavily on corticosteroids and supportive interventions like physical therapy and cardiac monitoring. There are exon-skipping drugs (therapies that help the body skip over genetic errors), but they only work for about 27% of the DMD population because each one targets a specific mutation.
That's why gene therapy matters so much here. Elevidys is the only FDA-approved gene therapy for DMD. It uses a modified virus to deliver a shortened version of the dystrophin gene, the one that's broken in Duchenne patients. When it works, it can produce functional protein that these kids' bodies can't make on their own.
But competitors are circling. REGENXBIO (RGX-202) is in late-stage development. Solid Biosciences and Genethon have their own AAV-based programs moving through the pipeline. If Elevidys keeps accumulating safety baggage, the next entrant with a cleaner profile could steal significant market share.
What Happens Now
Sarepta is betting that Elevidys revenue will stabilize now that the label restriction has been in place for over a year and physicians have adjusted their patient selection. The company also hopes its siRNA platform can eventually diversify revenue beyond a single product.
But the math is unforgiving. A black box warning scares doctors. Scared doctors write fewer prescriptions. Fewer prescriptions mean less revenue. Less revenue means more cost cuts. It's a cycle that's hard to break, especially when your stock is trading at $20 and you just told a third of your employees to clean out their desks.
The gene therapy dream isn't dead at Sarepta. But it's on life support, hooked up to a shrinking pipeline and a product that now carries pharma's most ominous label. For the families counting on this technology, the stakes couldn't be higher. For investors, the question is simple: can Sarepta stabilize before the next shoe drops?
Clinical & Regulatory5 min read
The U.S. Government Just Told Lab Mice to Start Updating Their Résumés
HHS just dropped $88 million and 20+ federal initiatives to move drug development away from animal testing and toward AI, organoids, and organ-on-a-chip systems. The lab mice might want to start networking.
